VERTAVIS Drug Patent Profile
✉ Email this page to a colleague
When do Vertavis patents expire, and when can generic versions of Vertavis launch?
Vertavis is a drug marketed by Medpointe Pharm Hlc and is included in one NDA.
The generic ingredient in VERTAVIS is veratrum viride root. There is one drug master file entry for this compound. Additional details are available on the veratrum viride root profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VERTAVIS?
- What are the global sales for VERTAVIS?
- What is Average Wholesale Price for VERTAVIS?
Summary for VERTAVIS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | VERTAVIS at DailyMed |
US Patents and Regulatory Information for VERTAVIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medpointe Pharm Hlc | VERTAVIS | veratrum viride root | TABLET;ORAL | 005691-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
